In the case of hematological cancer, when CD19 CAR‐T cells are infused, they initially encounter CD19 targets and start to be activated and expand.[3] However, the question remains as to what happens in the case of solid tumors. This evidence concerns the gene CD19 and hematopoietic and lymphoid cell neoplasm.